Cargando…

EGFR amplification induces sensitivity to antiEGFR therapy in pancreatic acinar cell carcinoma

Pancreatic acinar cell carcinoma (PACC) is a rare cancer. When the tumor is metastatic, few therapeutic options are available. Precision medicine using next-generation sequencing is defined by the administration of drugs based on the tumor genetic mutations. The usage of precision medicine for findi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Richard, Corentin, Niogret, Julie, Boidot, Romain, Ghiringhelli, Francois
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5900454/ https://www.ncbi.nlm.nih.gov/pubmed/29666669 http://dx.doi.org/10.4251/wjgo.v10.i4.103

Ejemplares similares

Association of Anti-EGFR Antibody and MEK Inhibitor in Gynecological Cancer Harboring RAS Mutation: A Case Series
por: Niogret, Julie, et al.
Publicado: (2022)

Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
por: Derangère, Valentin, et al.
Publicado: (2016)

Durable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genes
por: Dalens, Lorraine, et al.
Publicado: (2023)

Uncommon EGFR mutations in lung carcinoma: features and treatment outcomes in a retrospective French cohort
por: Tankere, Pierre, et al.
Publicado: (2022)

Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair protein
por: Ghiringhelli, Francois, et al.
Publicado: (2016)

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
por: Secq, V, et al.
Publicado: (2014)

EGFR alterations and response to anti-EGFR therapy: is it a matter of gene amplification or gene copy number gain?
por: Sesboüé, R, et al.
Publicado: (2012)

Reply: EGFR alterations and response to anti-EGFR therapy: is it a matter of gene amplification or gene copy number gain?
por: Ålgars, A, et al.
Publicado: (2012)

Strong nuclear EGFR expression in colorectal carcinomas is associated with cyclin-D1 but not with gene EGFR amplification
por: Dekanić, Andrea, et al.
Publicado: (2011)

Is There a Role for Large Exome Sequencing in the Management of Metastatic Non-Small Cell Lung Cancer: A Brief Report of Real Life
por: Dalens, Lorraine, et al.
Publicado: (2022)

Pancreatic Acinar Cell Carcinoma
por: Béchade, Dominique, et al.
Publicado: (2016)

PIK3CA and PIK3R1 tumor mutational landscape in a pan-cancer patient cohort and its association with pathway activation and treatment efficacy
por: Tharin, Zoé, et al.
Publicado: (2023)

EGFR Gene Amplification and Protein Expression in Invasive Ductal Carcinoma of the Breast
por: Hwangbo, Won, et al.
Publicado: (2013)

The prognostic value of EGFR overexpression and amplification in Esophageal squamous cell Carcinoma
por: Jiang, Dongxian, et al.
Publicado: (2015)

EGFR Amplification and Glioblastoma Stem-Like Cells
por: Liffers, Katrin, et al.
Publicado: (2015)

Revisiting Epidermal Growth Factor Receptor (EGFR) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies
por: Kato, Shumei, et al.
Publicado: (2019)

HSP90 inhibition overcomes EGFR amplification‐induced resistance to third‐generation EGFR‐TKIs
por: Watanabe, Sho, et al.
Publicado: (2021)

Update on Anti-EGFR Therapy
por: Chua, Daniel, et al.
Publicado: (2009)

Therapeutic Efficacy of GC1118, a Novel Anti-EGFR Antibody, against Glioblastoma with High EGFR Amplification in Patient-Derived Xenografts
por: Lee, Kyoungmin, et al.
Publicado: (2020)

A multicenter, phase II trial of GC1118, a novel anti‐EGFR antibody, for recurrent glioblastoma patients with EGFR amplification
por: Choi, Seung Won, et al.
Publicado: (2023)

Uncertainty quantification in the radiogenomics modeling of EGFR amplification in glioblastoma
por: Hu, Leland S., et al.
Publicado: (2021)

Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination
por: Grapin, Mathieu, et al.
Publicado: (2019)

Are Mutations of the EGFR Gene Promising Predictive Markers for Anti-EGFR mAbs in Colorectal Carcinomas?
por: Park, Dong-Guk
Publicado: (2011)

Transcriptome analysis of T(H)2 CD4(+) T cells differentiated from wild-type and NLRP3KO mice
por: Bruchard, Mélanie, et al.
Publicado: (2015)

Papillocystic Variant of Acinar Cell Pancreatic Carcinoma
por: Radhi, Jasim, et al.
Publicado: (2010)

Pancreatic acinar cell carcinoma–induced panniculitis
por: Singh, Sanminder, et al.
Publicado: (2018)

Defining EGFR amplification status for clinical trial inclusion
por: French, Pim J, et al.
Publicado: (2019)

The tyrosine phosphatase PTPRO sensitizes colon cancer cells to anti-EGFR therapy through activation of SRC-mediated EGFR signaling
por: Asbagh, Layka Abbasi, et al.
Publicado: (2014)

Impact of proton therapy on antitumor immune response
por: Mirjolet, Céline, et al.
Publicado: (2021)

EGFR blockade confers sensitivity to cabozantinib in hepatocellular carcinoma
por: Ma, Xuhui, et al.
Publicado: (2022)

Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
por: Wang, Wenxian, et al.
Publicado: (2019)

EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target
por: Iida, K, et al.
Publicado: (2011)

Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC
por: Dufort, Sandrine, et al.
Publicado: (2011)

Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs
por: Gelardi, T, et al.
Publicado: (2008)

Baseline splenic volume as a surrogate marker of FOLFIRINOX efficacy in advanced pancreatic carcinoma
por: Aarnink, Anne, et al.
Publicado: (2018)

Heterogeneity of resistant mechanisms in an EGFR-TKI relapsed patient with EGFR amplification and response to nimotuzumab: A case report
por: Li, Yan, et al.
Publicado: (2022)

Bone metastatic carcinoma with EGFR amplification and mutation: A case report and literature review
por: Du, Hong-Juan, et al.
Publicado: (2023)

Clinicopathological Characteristics And EGFR-TKIs Efficacies In Lung Squamous Cell Carcinoma Patients Harboring An EGFR Sensitizing Mutation
por: Zhou, Shaozhang, et al.
Publicado: (2019)

Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs
por: Bianco, R, et al.
Publicado: (2008)

Cinobufagin Is a Selective Anti-Cancer Agent against Tumors with EGFR Amplification and PTEN Deletion
por: He, Kunyan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gurmnk4hl0dkdtmcmcetk8ln3t